Microsoft word - pt agenda for 10-23-13.docx

All agenda item supporting documentation i s available for public review at Kern Health Systems in Stockdale Highway, Bakersfield, 93311 during regular s, 8:00 a.m. – 5:00 p.m., Monday through Friday, following the posting of the agenda. tes to an agenda item for an open session of any regular meeting that is distributed after the agenda is posted and prior to the meeting will also be available COMMITTEE MEMBERS: Alison Bell, Pharm. D; Michelle Church, Pharm. D; Ryan Gates, Pharm. D; Dilbaugh Gehlawat, M.D.; Kimberly Hoffman, Pharm. D; Sam Ratnayake, M.D.; Vasanthi Srinivas, M.D.; Shanna Treanor, M.D.; Bruce Wearda, R.Ph., Director of Pharmacy CONSENT AGENDA/OPPORTUNITY FOR PUBLIC COMMENT: ALL ITEMS LISTED WITH A "CA" ARE CONSIDERED TO BE ROUTINE AND NON-CONTROVERSIAL BY KERN HEALTH SYSTEMS STAFF. THE "CA" REPRESENTS THE CONSENT AGENDA. CONSENT ITEMS WILL BE CONSIDERED FIRST AND MAY BE APPROVED BY ONE MOTION IF NO COMMITTEE MEMBER OR AUDIENCE WISHES TO COMMENT OR ASK QUESTIONS. IF COMMENT OR DISCUSSION IS DESIRED BY ANYONE, THE ITEM WILL BE REMOVED FROM THE CONSENT AGENDA AND WILL BE CONSIDERED IN LISTED SEQUENCE WITH AN OPPORTUNITY FOR ANY MEMBER OF THE PUBLIC TO ADDRESS THE COMMITTEE MEMBERS CONCERNING THE ITEM BEFORE ACTION IS TAKEN. STAFF RECOMMENDATION SHOWN IN CAPS AgendaP&T Committee Page
This portion of the meeting is reserved for persons to address the Committee Members on any matter not on this agenda but under the jurisdiction of the Committee Members. Committee Members may respond briefly to statements made or questions posed. They may ask a question for clarification; make a referral to staff for factual information or request staff to report back to the Committee Members at a later meeting. Also, the Committee Members may take action to direct the staff to place a matter of business on a future agenda. SPEAKERS ARE LIMITED TO TWO MINUTES. PLEASE STATE AND SPELL YOUR NAME BEFORE MAKING YOUR PRESENTATION. THANK YOU! COMMITTEE MEMBER ANNOUNCEMENTS OR REPORTS On their own initiative, Committee Members may make an announcement or a report on their own activities. They may ask a question for clarification, make a referral to staff or take action to have staff place a matter of business on a future agenda (Gov. Code Sec. 54954.2[a]) Minutes for KHS Pharmacy &Therapeutics Committee meeting on April 23, 2013 – APPROVE Minutes for KHS Pharmacy & Therapeutics Committee meeting on July 24, 2013 – APPROVE Update on status of Healthy Families Conversion - Report on Fluconazole utilization and cost - Review gender limits on zolpidem. Align with new FDA restriction of 5mg for females – Review Angiotensin II Receptor Blocker (ARB) utilization. Allow for generics and generics with HCTZ. – APPROVE AgendaP&T Committee Page
Review antiemetic medication class. Recommend to leave unchanged the current restriction of limit of 3 days’ worth of ondansetron – Review cyanocobalamin (Cbl) B-12 Criteria. Require documentation demonstrating deficiency. Managing with oral preparations first prior to approving injections. – Review Triptan class, modify KHS formulary to cover naratriptan, sumatriptan, and rizatriptan. – Closed Session regarding peer review of a provider (Welfare and Institutions Code Section 14087.38(o)) – Report on actions taken in Closed Session – ADJOURN TO JANUARY 29, 2014 IF COMMITTEE APPROVES DATE AgendaP&T Committee Page
(Government Code Section 54953.2)
The meeting facilities at Kern Health Systems are accessible to persons with disabilities. Disabled individuals who need special assistance to attend or participate in a meeting of the Board of Directors may request assistance at the Kern Health Systems office, 9700 Stockdale Highway, Bakersfield, California or by calling (661) 664-5000. Every effort will be made to reasonably accommodate individuals with disabilities by making meeting material available in alternative formats. Requests for assistance should be made five (5) working days in advance of a meeting whenever possible.



Publication Higher Elastase Activity Associated with Lower IL-1 s GCF from Juvenile Systemic Lupus PatientsCarlos Marcelo S. Figueredoa,b/Alessandra Areasa/Flávio R.Sztajnbokc/Vivian Micelia/Letícia A. Mirandab/Ricardo G. Fischera/Anders GustafssonbPurpose: Theour aim was to evaluate the expression of interleukin-18 (IL-18) and, interleukin-1-beta (IL-1b‚) and the amountof elastase ac

Mdn090 60.62

Annals of Oncology 19 (Supplement 2): ii60–ii62, 2008Chronic lymphocytic leukemia: ESMO ClinicalRecommendations for diagnosis, treatment and follow-upB. Eichhorst1, M. Hallek1 & M. Dreyling2On behalf of the ESMO Guidelines Working Group*1Department of Internal Medicine I, University of Ko¨ln, Ko¨ln, Germany; 2Department of Medicine III, University Hospital Grosshadern, Munich, Germany

Copyright © 2010-2014 Medical Articles